Drugs / JZP3507
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07533942 | Jun 2026 → Oct 2028 expected | meningioma | Jazz Pharmaceuticals | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JZP3507 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07533942 ↗ |
| Route | Oral | “Participants will receive oral JZP3507 monotherapy” NCT07533942 ↗ |